Citadel Advisors’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21M | Buy |
10,087,770
+3,294,150
| +48% | +$7.23M | ﹤0.01% | 2518 |
|
|
2026
Q1 | $16.6M | Sell |
6,793,620
-5,317,800
| -44% | -$10.7M | ﹤0.01% | 2564 |
|
|
2025
Q4 | $16.6M | Sell |
12,111,420
-1,860,137
| -13% | -$2.45M | ﹤0.01% | 2590 |
|
|
2025
Q3 | $17.3M | Buy |
13,971,557
+3,718,951
| +36% | +$4.43M | ﹤0.01% | 2519 |
|
|
2025
Q2 | $11.6M | Buy |
10,252,606
+49,277
| +0.5% | +$65.5K | ﹤0.01% | 2821 |
|
|
2025
Q1 | $14.9M | Buy |
10,203,329
+4,854,233
| +91% | +$9.15M | ﹤0.01% | 2367 |
|
|
2024
Q4 | $11.4M | Buy |
5,349,096
+309,502
| +6% | +$763K | ﹤0.01% | 2812 |
|
|
2024
Q3 | $14.1M | Buy |
5,039,594
+2,593,091
| +106% | +$6.91M | ﹤0.01% | 2454 |
|
|
2024
Q2 | $5.7M | Sell |
2,446,503
-666,722
| -21% | -$1.97M | ﹤0.01% | 3544 |
|
|
2024
Q1 | $13.9M | Sell |
3,113,225
-940,001
| -23% | -$3.92M | ﹤0.01% | 2489 |
|
|
2023
Q4 | $13M | Sell |
4,053,226
-62,404
| -2% | -$177K | ﹤0.01% | 2508 |
|
|
2023
Q3 | $13M | Sell |
4,115,630
-624,711
| -13% | -$2.74M | ﹤0.01% | 2354 |
|
|
2023
Q2 | $23.6M | Buy |
4,740,341
+391,838
| +9% | +$2.12M | ﹤0.01% | 1722 |
|
|
2023
Q1 | $21.5M | Buy |
4,348,503
+3,808,199
| +705% | +$24.4M | ﹤0.01% | 1846 |
|
|
2022
Q4 | $3.4M | Sell |
540,304
-352,551
| -39% | -$3.26M | ﹤0.01% | 4544 |
|
|
2022
Q3 | $9.6M | Buy |
892,855
+811,492
| +997% | +$11M | ﹤0.01% | 2828 |
|
|
2022
Q2 | $927K | Sell |
81,363
-2,534,748
| -97% | -$22.5M | ﹤0.01% | 7200 |
|
|
2022
Q1 | $23.8M | Buy |
2,616,111
+241,614
| +10% | +$2.52M | ﹤0.01% | 1785 |
|
|
2021
Q4 | $35.4M | Buy |
2,374,497
+2,064,988
| +667% | +$36.4M | 0.01% | 1463 |
|
|
2021
Q3 | $7.95M | Sell |
309,509
-101,301
| -25% | -$2.41M | ﹤0.01% | 3461 |
|
|
2021
Q2 | $10.7M | Buy |
410,810
+379,323
| +1,205% | +$10.8M | ﹤0.01% | 2971 |
|
|
2021
Q1 | $1.11M | Sell |
31,487
-272,366
| -90% | -$9.19M | ﹤0.01% | 7850 |
|
|
2020
Q4 | $7.67M | Buy |
303,853
+240,364
| +379% | +$7.83M | ﹤0.01% | 3008 |
|
|
2020
Q3 | $2.39M | Sell |
63,489
-33,851
| -35% | -$1.28M | ﹤0.01% | 4395 |
|
|
2020
Q2 | $4.17M | Buy |
97,340
+42,054
| +76% | +$1.52M | ﹤0.01% | 3341 |
|
|
2020
Q1 | $1.07M | Sell |
55,286
-960
| -2% | -$22.9K | ﹤0.01% | 5210 |
|
|
2019
Q4 | $1.46M | Sell |
56,246
-295,648
| -84% | -$8.14M | ﹤0.01% | 4919 |
|
|
2019
Q3 | $9.6M | Sell |
351,894
-91,683
| -21% | -$2.61M | ﹤0.01% | 2267 |
|
|
2019
Q2 | $11.9M | Sell |
443,577
-220,926
| -33% | -$6.16M | 0.01% | 1971 |
|
|
2019
Q1 | $19.2M | Buy |
664,503
+293,885
| +79% | +$8.53M | 0.01% | 1375 |
|
|
2018
Q4 | $10M | Buy |
+370,618
| New | +$9.8M | 0.01% | 1893 |
|
Other funds holding ALLO
Citadel Advisors's ALLO Position: Q2 2026 in Review
Citadel Advisors increased its Allogene Therapeutics (ALLO) stake by 48% in Q2 2026, buying an estimated $7.23M and bringing the position to 10,087,770 shares worth $21M. The position accounts for ﹤0.01% of the portfolio, ranked #2518.
Citadel Advisors first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $35.4M in Q4 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.
- Citadel Advisors held 10,087,770 shares of Allogene Therapeutics worth $21M as of Q2 2026.
- Citadel Advisors bought 3,294,150 Allogene Therapeutics shares in Q2 2026, an estimated $7.23M.
- Allogene Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2518 holding.
- Citadel Advisors first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
- Citadel Advisors's Allogene Therapeutics position peaked at $35.4M in Q4 2021.
- 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.